Dostarlimab

Monoclonal antibody

Also known as TSR-042

Approvedregulatory verdict

Evidence outlook

Approved: Endometrial Cancer, Rectal Cancer [accelerated]

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Non-Small Cell Lung Cancer · Phase 3

Also approved (3)
US
  • JEMPERLI (dostarlimab-gxly): adults with stage II or III mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer (accelerated approval)Outside this platform's coverageonclive.com
  • Mismatch Repair Deficient Recurrent or Advanced Solid Tumors JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies ( 14.3 )] . Continued approval for this indication may be contingent upon verification
    FDA label
Product first approved 2021
EU
  • Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Endometrial Cancer
NCT07860450 · GlaxoSmithKline
2026-11-12 – 2032-11-05 · Endometrial Carcinoma, Neoplasms, Endometrial
What this study did
NCT07684599 · GlaxoSmithKline
2026-09-24 – 2031-09-18 · Neoplasms, Endometrial
What this study did
NCT05201547 · ARCAGY/ GINECO GROUP
2022-04-15 – 2029-10 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
Rectal Cancer
NCT07740720 · GlaxoSmithKline
2026-12-17 – 2030-04-01 · Neoplasms, Rectal
What this study did
Other / comorbidity
NCT05855200 · GlaxoSmithKline
2023-08-01 – 2031-03-27 · Colonic Neoplasms, Neoplasms, Colon
What this study did
NCT06256588 · GlaxoSmithKline
2024-03-21 – 2029-10-26 · Neoplasms, Head and Neck
What this study did
NCT03602859 · Tesaro, Inc.
2018-10-11 – 2029-04-30 · Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
What this study did
NCT04679064 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-12-01 – 2025-01-01 · Ovarian Cancer
What this study did
NCT03806049 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2019-12 – 2024-12 · Ovarian Cancer
What this study did
Phase 2/3 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT03651206 · ARCAGY/ GINECO GROUP
2020-07-15 – 2029-03 · Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
What this study did
Phase 2 (55)
Endometrial Cancer
NCT07115927 · University College, London
2025-09-30 – 2031-01-31 · Endometrial Cancer
What this study did
NCT07108270 · GlaxoSmithKline
2025-11-27 – 2030-03-31 · Neoplasms, Endometrial
What this study did
NCT07013851 · Grupo Español de Investigación en Cáncer de Ovario
2025-10-01 – 2029-10-01 · MMRd/MSI-H Stage II-III Endometrial Cancer
What this study did
NCT06317311 · GlaxoSmithKline
2024-05-07 – 2028-09-30 · Carcinoma
What this study did
NCT06278857 · Queensland Centre for Gynaecological Cancer
2024-08-01 – 2028-06-30 · Endometrial Cancer Stage I, Mmr Deficiency, Endometrioid Endometrial Adenocarcinoma, Immune-related Adverse Event
What this study did
NCT04774419 · Memorial Sloan Kettering Cancer Center
2021-04-02 – 2027-02 · Endometrial Cancer
What this study did
NCT03016338 · University Health Network, Toronto
2017-11-06 – 2026-12 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05565378 · GlaxoSmithKline
2022-10-14 – 2027-12-06 · Lung Cancer, Non-Small Cell
What this study did
NCT04940637 · University of Turin, Italy
2020-12-23 – 2025-06-30 · Lung Cancer, Mesothelioma
What this study did
NCT04581824 · GlaxoSmithKline
2020-11-19 – 2024-09-10 · Lung Cancer, Non-Small Cell
What this study did
NCT06926673 · GlaxoSmithKline
2021-12-23 – 2024-05-02 · Neoplasms
What this study did
NCT03308942 · Tesaro, Inc.
2017-09-29 – 2021-08-31 · Neoplasms
What this study did
Rectal Cancer
NCT06640049 · GlaxoSmithKline
2024-10-17 – 2031-04-15 · Neoplasms, Rectal
What this study did
NCT07381777 · Gruppo Oncologico Italiano di Ricerca Clinica
2026-01-31 – 2030-12-31 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT05723562 · GlaxoSmithKline
2023-04-03 – 2029-10-11 · Neoplasms, Rectal
What this study did
NCT05239546 · University of Iowa
2023-03-24 – 2029-06-30 · Colon Cancer, dMMR Colorectal Cancer
What this study did
NCT06365970 · Ibrahim Halil Sahin
2025-01-31 – 2028-01 · MMR-D/MSI-H Colorectal Cancers
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07408063 · University Health Network, Toronto
2026-04-27 – 2031-03-01 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT07336147 · Chang Gung Memorial Hospital
2025-12-22 – 2030-12-22 · Female
What this study did
NCT06333314 · UNICANCER
2024-07-23 – 2030-09 · Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT05700721 · M.D. Anderson Cancer Center
2023-06-02 – 2029-12-31 · Brain Metastases
What this study did
NCT06023862 · Yonsei University
2024-01-22 – 2029-12-31 · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell Carcinoma
What this study did
NCT04139902 · Diwakar Davar
2020-06-12 – 2029-12-15 · Melanoma Stage III, Melanoma Stage IV
What this study did
NCT04837209 · Massachusetts General Hospital
2021-07-21 – 2029-12-01 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT04584255 · Dana-Farber Cancer Institute
2021-01-21 – 2029-07-17 · Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
What this study did
NCT05855811 · Centre Leon Berard
2023-07-26 – 2029-03-26 · Recurrent Cancer, Primary Cancer, Second Cancer
What this study did
NCT05405192 · University of Miami
2023-03-01 – 2028-12-01 · Gestational Trophoblastic Neoplasia
What this study did
NCT06830239 · Universitaire Ziekenhuizen KU Leuven
2025-04-03 – 2028-12 · Colon Cancer Stage III
What this study did
NCT06059495 · GERCOR - Multidisciplinary Oncology Cooperative Group
2024-01-22 – 2028-09-01 · Adenocarcinoma - GEJ, Gastric Adenocarcinoma
What this study did
NCT03833479 · Grupo Español de Investigación en Cáncer de Ovario
2019-06-28 – 2028-07-31 · Cervical Cancer, Advanced Cancer
What this study did
NCT06757244 · Hopital Foch
2025-02-18 – 2028-02-18 · Pancreas Neoplasms
What this study did
NCT05526989 · H. Lee Moffitt Cancer Center and Research Institute
2022-12-28 – 2027-11 · Penile Carcinoma
What this study did
NCT03680508 · University of Hawaii
2019-12-19 – 2027-10 · Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
What this study did
NCT04068753 · University of Oklahoma
2020-02-26 – 2027-08 · Recurrent Cervix Cancer, Progressive Cervix Cancer
What this study did
NCT06238635 · Meghan Shea
2024-03-11 – 2027-07-15 · Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
What this study did
NCT04701307 · M.D. Anderson Cancer Center
2021-02-01 – 2027-04-30 · Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
What this study did
NCT05126342 · AGO Research GmbH
2023-11-01 – 2026-11-01 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT05870761 · Casey Cosgrove
2023-10-17 – 2026-07-31 · Recurrent Endometrial Serous Adenocarcinoma
What this study did
NCT04313504 · Trisha Wise-Draper
2020-11-04 – 2026-03-04 · Head and Neck Cancer
What this study did
NCT04983745 · West Cancer Center
2021-11-29 – 2025-08 · Homologous Recombination Deficient Solid Tumors
What this study did
NCT05065021 · University Health Network, Toronto
2023-02-23 – 2025-06-06 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
What this study did
NCT04493060 · Mayo Clinic
2020-12-28 – 2025-06-01 · Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03574779 · Tesaro, Inc.
2018-11-15 – 2025-03-31 · Ovarian Neoplasms
What this study did
NCT04779151 · Gustave Roussy, Cancer Campus, Grand Paris
2021-04-07 – 2025-02-25 · Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer, Biliary Tract Cancer, Platinum-sensitive Urothelial Bladder Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
What this study did
NCT03654833 · University of Leicester
2019-01-28 – 2024-03-15 · Mesothelioma, Malignant
What this study did
Phase 1/2 (11)
Endometrial Cancer
NCT05559879 · University of Alabama at Birmingham
2023-08-20 – 2027-04 · Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
What this study did
NCT06385548 · Vall d'Hebron Institute of Oncology
2024-05 – 2026-04 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06879717 · iOnctura
2025-04-22 – 2028-01 · Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
What this study did
Other / comorbidity
NCT05784012 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2023-11-13 – 2029-03 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06796907 · GlaxoSmithKline
2025-03-04 – 2028-10-10 · Tumours, Gynecological
What this study did
NCT06065462 · M.D. Anderson Cancer Center
2023-11-10 – 2027-10-01 · Ovarian Clear Cell Carcinoma
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT06521567 · GlaxoSmithKline
2025-03-06 – 2026-10-13 · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
What this study did
NCT05060432 · iTeos Belgium SA
2021-09-06 – 2025-07 · Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
What this study did
NCT06655818 · GlaxoSmithKline
2021-03-09 – 2024-02-14 · Relapsed/Refractory Multiple Myeloma
What this study did
Phase 1 (17)
Endometrial Cancer
NCT03955978 · Washington University School of Medicine
2019-10-15 – 2029-02-01 · Endometrial Cancer, Cancer of the Endometrium
What this study did
NCT05819892 · M.D. Anderson Cancer Center
2023-07-17 – 2028-03-01 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03307785 · Tesaro, Inc.
2017-10-12 – 2024-12-11 · Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
What this study did
Rectal Cancer
NCT04926324 · University of Iowa
2022-07-07 – 2025-11-24 · Rectal Neoplasms, Rectal Neoplasm Malignant
What this study did
Other / comorbidity
NCT06551142 · GlaxoSmithKline
2024-09-30 – 2029-06-08 · Neoplasms
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT04673448 · University of Washington
2021-10-18 – 2027-09-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
What this study did
NCT05277051 · GlaxoSmithKline
2022-03-22 – 2027-08-31 · Neoplasms
What this study did
NCT02817633 · Tesaro, Inc.
2016-07-08 – 2027-03-01 · Neoplasms
What this study did
NCT04446351 · GlaxoSmithKline
2020-06-25 – 2026-12-31 · Neoplasms
What this study did
NCT05646082 · Imperial College London
2023-05-26 – 2026-12-31 · Refractory HIV Associated Kaposi Sarcoma
What this study did
NCT03843359 · GlaxoSmithKline
2019-03-12 – 2026-01-09 · Neoplasms
What this study did
NCT05980416 · Elevation Oncology
2023-08-10 – 2025-06-02 · Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
What this study did
NCT04544995 · GlaxoSmithKline
2020-10-06 – 2025-04-23 · Neoplasms
What this study did
NCT02723955 · GlaxoSmithKline
2016-06-23 – 2023-07-05 · Neoplasms
What this study did
NCT03250832 · Tesaro, Inc.
2017-08-08 – 2023-02-13 · Neoplasms
What this study did
Phase 4 (2)
Endometrial Cancer
NCT07652515 · GlaxoSmithKline
2026-08-17 – 2030-08-30 · Neoplasms, Endometrial
What this study did
NCT06897527 · GlaxoSmithKline
2025-07-15 – 2027-01-13 · Neoplasms, Endometrial
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Rectal Cancer
NCT06762405 · Centre Hospitalier Universitaire Dijon
2025-02-06 – 2030-09 · Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Endometrial Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dostarlimab: this drugApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
SerabelisibPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
IMGN-151Phase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(44 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dostarlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (4)
Phase 2Penile CarcinomaRecruiting
Est. primary completion 2026-11 · NCT05526989 · CT.gov ↗
What to watch
Phase 2Neoplasms, ColonRecruiting
Est. primary completion 2026-11-23 · NCT06567782 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2026-11-30 · NCT04165772 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical CarcinomaActive not recruiting
Est. primary completion 2026-12-01 · NCT06238635 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-14 · NCT06317311 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2026-12-31 · NCT04446351 · CT.gov ↗
What to watch
2027 (16)
January 2027 (2)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT06879717 · CT.gov ↗
What to watch
Phase 4Endometrial CancerNot yet recruiting
Est. primary completion 2027-01-13 · NCT06897527 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-02 · NCT04774419 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT04837209 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05784012 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
Phase 1Endometrial CancerRecruiting
Est. primary completion 2027-03-01 · NCT05819892 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Endometrial CancerRecruiting
Est. primary completion 2027-04 · NCT05559879 · CT.gov ↗
What to watch
Phase 2Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT04701307 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2/3Ovarian Carcinosarcoma, Endometrial CarcinosarcomaRecruiting
Est. primary completion 2027-06 · NCT03651206 · CT.gov ↗
What to watch
Phase 1/2Tumours, GynecologicalRecruiting
Est. primary completion 2027-06-21 · NCT06796907 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06023862 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1/2Ovarian Clear Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT06065462 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2027-10-24 · NCT06640049 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Colon Cancer Stage IIIRecruiting
Est. primary completion 2027-12 · NCT06830239 · CT.gov ↗
What to watch
2028 (10)
February 2028 (1)
Phase 2Pancreas NeoplasmsRecruiting
Est. primary completion 2028-02-18 · NCT06757244 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2FemaleRecruiting
Est. primary completion 2028-06-22 · NCT07336147 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2028-06-30 · NCT05239546 · CT.gov ↗
What to watch
Phase 3Neoplasms, Head and NeckRecruiting
Est. primary completion 2028-06-30 · NCT06256588 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07381777 · CT.gov ↗
What to watch
Phase 2Recurrent Cancer, Primary Cancer, Second CancerRecruiting
Est. primary completion 2028-07-26 · NCT05855811 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Advanced CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT03833479 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Adenocarcinoma - GEJ, Gastric AdenocarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT06059495 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma …Recruiting
Est. primary completion 2028-10 · NCT06333314 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
2029 (4)
March 2029 (2)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2029-03-01 · NCT07013851 · CT.gov ↗
What to watch
Phase 3Colonic Neoplasms, Neoplasms, ColonRecruiting
Est. primary completion 2029-03-19 · NCT05855200 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Brain MetastasesRecruiting
Est. primary completion 2029-12-31 · NCT05700721 · CT.gov ↗
What to watch
2030 (7)
March 2030 (2)
Phase 3Rectal CancerNot yet recruiting
Est. primary completion 2030-03-13 · NCT07740720 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2030-03-31 · NCT07108270 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2030-04-30 · NCT07115927 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07408063 · CT.gov ↗
What to watch
August 2030 (1)
Phase 4Endometrial CancerNot yet recruiting
Est. primary completion 2030-08-30 · NCT07652515 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Endometrial CancerNot yet recruiting
Est. primary completion 2030-11-05 · NCT07860450 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026ApprovalFDA approves Jemperli under accelerated approval in dMMR locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026Filing acceptedFDA accepts Jemperli sBLA in dMMR/MSI-H locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026Priority reviewFDA grants priority review to Jemperli sBLA in locally advanced rectal cancer
US, FDA · Source ↗
13 July 2026Topline resultPhase 2 AZUR-1 met its primary objective in dMMR/MSI-H rectal cancer
6 August 2025Topline resultCOSTAR Lung (NCT04655976) did not meet its overall survival primary endpoint
GlaxoSmithKline · Source ↗
20 December 2024Topline resultFIRST trial meets primary PFS endpoint
GSK · Source ↗